Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Free Cash Flow (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Free Cash Flow for 5 consecutive years, with -$43.5 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 204.28% to -$43.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$171.2 million through Dec 2025, down 1418.48% year-over-year, with the annual reading at -$171.2 million for FY2025, 1418.48% down from the prior year.
  • Free Cash Flow hit -$43.5 million in Q4 2025 for ARS Pharmaceuticals, down from -$41.5 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $41.7 million in Q4 2024 to a low of -$45.4 million in Q2 2025.
  • Historically, Free Cash Flow has averaged -$13.8 million across 5 years, with a median of -$13.6 million in 2023.
  • Biggest five-year swings in Free Cash Flow: surged 338.45% in 2024 and later plummeted 519.94% in 2025.
  • Year by year, Free Cash Flow stood at $28.7 million in 2021, then crashed by 172.21% to -$20.7 million in 2022, then rose by 15.5% to -$17.5 million in 2023, then soared by 338.45% to $41.7 million in 2024, then tumbled by 204.28% to -$43.5 million in 2025.
  • Business Quant data shows Free Cash Flow for SPRY at -$43.5 million in Q4 2025, -$41.5 million in Q3 2025, and -$45.4 million in Q2 2025.